Metformin - For the dermatologist

被引:35
作者
Bubna, Aditya Kumar [1 ]
机构
[1] Sri Ramachandra Univ, Dept Dermatol, Madras, Tamil Nadu, India
关键词
Hyperandrogenism; hyperinsulinemia; hyperpigmentary disorders; metformin; skin cancer; POLYCYSTIC-OVARY-SYNDROME; SQUAMOUS-CELL CARCINOMA; GROWTH-FACTOR-I; INSULIN-RESISTANCE; ACANTHOSIS NIGRICANS; SIGNALING PATHWAY; ANDROGEN EXCESS; INHIBITION; THERAPY; GIRLS;
D O I
10.4103/0253-7613.174388
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Metformin though primarily an antidiabetic drug, has found to play an important role in a number of cutaneous disorders. Because of its role in improving hyperinsulinemia, it has proven beneficial in hormonal acne, hidradenitis suppurativa (HS) and acanthosis nigricans. Its antiandrogenic properties further serve as an add-on to the conventional management of hirsutism associated with polycystic ovarian syndrome. Very recently, systemic usage of metformin for psoriasis and cutaneous malignancies has shown promising results. Interestingly, metformin has also been topically used in hyperpigmentary disorders with pertinent levels of improvement and happens to be the most recent addition to the list of dermatologic indications. Though an oral hypoglycemic agent to begin with, metformin today has proven to be a boon for dermatologists.
引用
收藏
页码:4 / 10
页数:7
相关论文
共 46 条
  • [1] Long-standing hidradenitis suppurativa treated effectively with metformin
    Arun, B.
    Loffeld, A.
    [J]. CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2009, 34 (08) : 920 - 921
  • [2] Atabek ME, 2008, J PEDIATR ENDOCR MET, V21, P339
  • [3] Lichen planus associated with metformin therapy
    Azzam, H
    Bergman, R
    FriedmanBirnbaum, R
    [J]. DERMATOLOGY, 1997, 194 (04) : 376 - 376
  • [4] Barbato Mariana Tremel, 2012, An. Bras. Dermatol., V87, P97
  • [5] Metformin and liraglutide ameliorate high glucose-induced oxidative stress via inhibition of PKC-NAD(P)H oxidase pathway in human aortic endothelial cells
    Batchuluun, Battsetseg
    Inoguchi, Toyoshi
    Sonoda, Noriyuki
    Sasaki, Shuji
    Inoue, Tomoaki
    Fujimura, Yoshinori
    Miura, Daisuke
    Takayanagi, Ryoichi
    [J]. ATHEROSCLEROSIS, 2014, 232 (01) : 156 - 164
  • [6] Metformin: A Potential Drug to Treat Hyperpigmentation Disorders
    Belisle, Elisabeth S.
    Park, Hee-Young
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2014, 134 (10) : 2488 - 2491
  • [7] Bellot-Rojas Paula, 2006, J Drugs Dermatol, V5, P884
  • [8] Bermudez-Pirela Valmore J, 2007, Am J Ther, V14, P194, DOI 10.1097/01.pap.0000249909.54047.0e
  • [9] Metformin Blocks Melanoma Invasion and Metastasis Development in AMPK/p53-Dependent Manner
    Cerezo, Michael
    Tichet, Melanie
    Abbe, Patricia
    Ohanna, Mickael
    Lehraiki, Abdelali
    Rouaud, Florian
    Allegra, Maryline
    Giacchero, Damien
    Bahadoran, Philippe
    Bertolotto, Corine
    Tartare-Deckert, Sophie
    Ballotti, Robert
    Rocchi, Stephane
    [J]. MOLECULAR CANCER THERAPEUTICS, 2013, 12 (08) : 1605 - 1615
  • [10] Metformin, an Antidiabetic Agent Reduces Growth of Cutaneous Squamous Cell Carcinoma by Targeting mTOR Signaling Pathway
    Chaudhary, Sandeep C.
    Kurundkar, Deepali
    Elmets, Craig A.
    Kopelovich, Levy
    Athar, Mohammad
    [J]. PHOTOCHEMISTRY AND PHOTOBIOLOGY, 2012, 88 (05) : 1149 - 1156